TGA approves name change of COVID-19 Vaccine AstraZeneca to VAXZEVRIA

The Therapeutic Goods Administration (TGA), part of the Department of Health, has approved AstraZeneca's submission to change the name of its COVID-19 Vaccine AstraZeneca to VAXZEVRIA.

The name is now consistent with that used overseas, including in the European Union and Canada. This is expected to alleviate confusion and further clarify that the vaccine produced by CSL and Seqirus in Melbourne is the same as that produced internationally. This name change will also help facilitate international recognition for Australians who have been vaccinated with the AstraZeneca vaccine.

Importantly, this is the only change to the vaccine. All other aspects, such as manufacturing and quality control, are unchanged and align with the way the vaccine is produced in other jurisdictions.

At this stage, it is estimated that supply in Australia of the VAXZEVRIA-branded product will commence in late 2021. Once supply of the vaccine commences under the new name, the vaccine will no longer be supplied under the original name. Some stock with the original name may still be in use after the name change.

Contact for members of the media:

• Email: news@health.gov.au
• Phone: 02 6289 7400